United Therapeutics prevails in dry powder inhaler patent litigation against Liquidia Technologies.
United Therapeutics Corporation announced that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics’ U.S. patents 9,593,066 (the ’066 patent) and 10,716,793 (the ’793 patent)
This litigation concerns whether Liquidia Technologies, Inc.’s proposed treprostinil inhalation powder, Yutrepia, would infringe the ’066 and ’793 patents.
The Court determined that Liquidia would induce infringement of various claims of the ’793 patent by marketing Yutrepia. The ‘793 patent relates to a method of administering treprostinil via inhalation. The Court also concluded that Liquidia failed to prove that any claim of the ’793 patent at issue is invalid. As a result of the Court’s decision, United Therapeutics expects the Court to enter an injunction barring the FDA from granting final approval for Yutrepia until expiration of the ’793 patent, May 14, 2027, as required by 35 U.S.C. § 271(e)(4)(A).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.